Medisan(SZ:002900) Shang Hai Zheng Quan Bao·2026-02-06 19:26Core Viewpoint - The announcement details the completion of the repurchase and cancellation of restricted stocks by Harbin Sanlian Pharmaceutical Co., Ltd., involving a total of 3,000 shares, which represents 0.0009% of the company's total share capital before the repurchase [2][11]. Group 1: Repurchase and Cancellation Details - The repurchase price for the restricted stocks was set at 6.48 yuan per share, totaling 19,440 yuan for the repurchase [2][10]. - Following the cancellation, the company's total share capital decreased from 316,357,550 shares to 316,354,550 shares [2][11]. - The repurchase was completed on February 6, 2026, as confirmed by the China Securities Depository and Clearing Corporation [2][10]. Group 2: Background of the Stock Incentive Plan - The 2022 stock incentive plan was approved by the board on July 29, 2022, and involved granting 6,775,183 shares to 175 eligible participants at a price of 6.98 yuan per share [3][5]. - The plan included provisions for repurchasing shares from participants who no longer met the eligibility criteria due to voluntary resignation [9][10]. - The company adjusted the repurchase price from 6.68 yuan to 6.48 yuan per share prior to the cancellation [10]. Group 3: Impact and Future Arrangements - The cancellation of 3,000 shares will not significantly impact the company's financial metrics or daily operations [12]. - The company will proceed with the necessary legal and regulatory procedures for the share cancellation and registration [12].